StudyFinder

Eliminating Monitor Overuse Trial (EMO Trial)

RECRUITING
I'm interested

2 months and over
This study is NOT accepting healthy volunteers
Population 1a: Hospital staff who complete study questionnaires.
Inclusion Criteria:
* Nurse or physician fluent in English and employed full-time by the hospital, affiliated practice, or affiliated university who cared for bronchiolitis patients on a unit participating in the trial during at least 5 days of the most recent bronchiolitis season * Hospital administrator fluent in English who oversaw the care of bronchiolitis on a local level (e.g. nurse manager) or a hospital level (e.g. Chief Quality and Safety Officer)
Exclusion Criteria:
• Under the direct supervision of study or site principal investigator(s) Population 1b: Hospital staff who participate in qualitative interviews In Aim 2, we will conduct semi-structured interviews with physicians and nurses who provide care to bronchiolitis patients in participating units at the 5 hospitals with the highest and 3 hospitals with the lowest sustainability (8 hospitals total; up to maximum of 8 interviews/hospital). Maximum anticipated enrollment 64. Inclusion criteria: * Nurses or Physicians who cared for bronchiolitis patients on a unit participating in the trial during at least 5 days of the most recent bronchiolitis season * Employed full-time by the hospital, affiliated practice, or affiliated university * Fluent in English Exclusion criteria: • No exclusion criteria Population 2a: Bronchiolitis patients directly observed while not receiving supplemental oxygen ("in room air," for primary trial outcome)
Inclusion Criteria:
* Infants and children 2 months through 23 months old * Hospitalized on non-ICU wards participating in the trial * Cared for by generalist inpatient services (e.g. general pediatrics, hospital medicine) * Primary diagnosis of bronchiolitis in most recent physician progress note * Not actively receiving supplemental oxygen ("in room air") * Last documented receipt of supplemental oxygen \>1 hour prior to direct observational data collection
Exclusion Criteria:
* Documented apnea or cyanosis during the current illness * Extreme prematurity (\<28 weeks completed gestation) * Cardiac disease * Pulmonary hypertension * Chronic lung disease * Home oxygen requirement * Neuromuscular disease * Immunodeficiency * Cancer * Severe Acute Respiratory Syndrome Coronavirus 2 (Covid-19 / SARS-CoV-2)-related illness (known or suspected, including multisystem inflammatory syndrome in children multi-system inflammatory syndrome in children (MIS-C) Population 2b: Bronchiolitis patients directly observed while receiving supplemental oxygen (for underuse evaluation).
Inclusion Criteria:
* Infants and children 2 months through 23 months old * Hospitalized on non-ICU wards participating in the trial * Cared for by generalist inpatient services (e.g. general pediatrics, hospital medicine) * Primary diagnosis of bronchiolitis in most recent physician progress note * Actively receiving ≥2 Liters/minute (2L/min) supplemental oxygen or 21% room air flow
Exclusion Criteria:
* Extreme prematurity (\<28 weeks completed gestation) * Cardiac disease * Pulmonary hypertension * Chronic lung disease * Home oxygen requirement * Neuromuscular disease * Immunodeficiency * Cancer * Severe Acute Respiratory Syndrome Coronavirus 2 \[Covid-19 / SARS-CoV-2 (known or suspected)\] Population 3: Parents or guardians of bronchiolitis patients who participate in qualitative interviews.
Inclusion Criteria:
* Their child was hospitalized for bronchiolitis on a unit participating in the trial during the most recent bronchiolitis season * Their child was found to be in room air during Aim 1 data collection * Fluent in English Exclusion criteria: • They are an employee of the hospital or a hospital volunteer

BEHAVIORAL: Educational Outreach, BEHAVIORAL: Audit & Feedback (unit level), BEHAVIORAL: Audit & Feedback (real time, individual-level), BEHAVIORAL: Clinical Pathway Integrated into Electronic Health Record

Bronchiolitis Acute Viral

pulse oximetry, deimplementation, cluster-randomized trial, effectiveness-implementation hybrid trial, implementation science

Christopher P Bonafide, MD, MSCE - bonafide@chop.edu
Lee, Clifton, C
NA
HM20022900
NCT05132322
See this study on ClinicalTrials.gov

Back